Active Ingredient History
Piperaquine is an antiparasitic drug used in combination with dihydroartemisinin to treat malaria. Piperaquine was developed under the Chinese National Malaria Elimination Programme in the 1960s and was adopted throughout China as a replacement for the structurally similar antimalarial drug chloroquine. Due to widespread parasite resistance to piperaquine, the drug fell out of use as a monotherapy, and is instead used as a partner drug for artemisinin combination therapy. Piperaquine kills parasites by disrupting the detoxification of host heme. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Anemia (Phase 4)
Anemia, Sickle Cell (Phase 2/Phase 3)
Cardiotoxicity (Phase 2)
Drug Combinations (Phase 1)
Drug Interactions (Phase 4)
Drugs, Investigational (Phase 2/Phase 3)
Elephantiasis, Filarial (Phase 3)
Fever (Phase 3)
Healthy Volunteers (Phase 4)
Helminthiasis (Phase 3)
HIV (Phase 3)
HIV Infections (Phase 4)
Hookworm Infections (Phase 3)
Infections (Phase 2)
Malaria (Phase 4)
Malaria, Falciparum (Phase 4)
Malaria Vaccines (Phase 2)
Malaria, Vivax (Phase 4)
Neoplasm Metastasis (Phase 3)
Parasitemia (Phase 2)
Parasitic Diseases (Phase 4)
Pharmacokinetics (Phase 4)
Plasmodium (Phase 4)
Plasmodium falciparum (Phase 4)
Plasmodium vivax (Phase 1/Phase 2)
Pregnancy (Phase 4)
Pregnancy Complications (Phase 4)
Scabies (Phase 3)
Stomach Neoplasms (Phase 3)
Strongyloidiasis (Phase 3)
Therapeutics (Phase 3)
Treatment Adherence and Compliance (Phase 4)
Treatment Outcome (Phase 4)
Trichomonas Vaginitis (Phase 3)
Tropical Medicine (Phase 3)
Vaginosis, Bacterial (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue